首页> 外文期刊>Archives of disease in childhood >P67?Impact of enantiomer-specific maturational changes in pharmacokinetics on the racemic ketorolac target trough concentration
【24h】

P67?Impact of enantiomer-specific maturational changes in pharmacokinetics on the racemic ketorolac target trough concentration

机译:P67对映体特异性成熟变化对药代动力学的影响对消旋酮咯酸目标谷浓度的影响

获取原文
       

摘要

Introduction Ketorolac is a racemic drug with analgesic effects specific to its S-enantiomer. This study aimed to describe enantiomer-specific maturational pharmacokinetics (PK). Simulations were performed to describe how S-ketorolac exposure in infants differs from adults, and how this affects the adult racemic analgesic trough threshold ECsub50/sub (EC50subthr-adult/sub, 0.37 mg/L) in infants (EC50subthr-infant/sub)when the same S-target is applied. Methods A population PK analysis (NONMEM 7.3) was performed based on 1020 plasma samples from 5 studies including 80 patients (adults, children, infants) following single intravenous ketorolac administration. Results S-ketorolac PK was best described with a 2-compartment model in infants and 3-compartment model in adults, while R-ketorolac PK was best described with a 2-compartment model in all. S-ketorolac clearance [mean population value: 3.45 L/h/56 kg] and central volume of distribution (V1) [4.27 L/56kg] increased exponentially with bodyweight (0.75, 0.59 respectively). R-ketorolac clearance [0.93 L/h/56kg], peripheral volume of distribution (V2) and inter-compartmental clearance (Q) increased exponentially with bodyweight (0.62, 1.20, 0.76 respectively), V1 [4.11 L/56kg] linearly with bodyweight. Simulations revealed EC50subthr-adult/sub (0.37 mg/L) contained 0.048 mg/L S-ketorolac as mean in typical adults (BW 48.6–99.6 kg), while EC50subthr-adult/sub contained 0.032–0.036 mg/L S-ketorolac in typical infants (BW 5.3–10.6 kg). To reach adult S-enantiomer concentration (0.048 mg/L) in typical infants (BW 5.3–10.6 kg), ECsub50thr-infant/sub should be 0.49–0.46 mg/L, respectively. Conclusion Enantiomer-specific maturational PK of ketorolac were described. Subsequent simulations displayed differences in proportion of S- and R-ketorolac on the racemic threshold ECsub50/sub. A The same S-ketorolac concentration necessitates a higher EC50subthr-infant/sub to EC50subthr-adult/sub.
机译:简介酮咯酸是一种外消旋药物,具有针对其S-对映体的止痛作用。这项研究旨在描述对映异构体特定的成熟药代动力学(PK)。进行了模拟,以描述婴儿中S-酮咯酸的暴露量与成年人之间的差异,以及这如何影响成年人的消旋止痛剂阈值EC 50 (EC50 thr-adult ,0.37 mg / L)应用于相同S-target的婴儿(EC50 thr-婴儿)。方法根据5项研究的1020份血浆样本进行了人群PK分析(NONMEM 7.3),其中包括80例患者(成人,儿童,婴儿),单次静脉内注射酮咯酸。结果S-酮咯酸PK在婴儿的2房模型中最能描述,而在成人的3隔室模型中则是2室模型中最好的描述。 S-酮咯酸清除率[平均人口价值:3.45 L / h / 56 kg]和中心分布体积(V1)[4.27 L / 56kg]与体重呈指数关系增加(分别为0.75、0.59)。 R-酮咯酸清除率[0.93 L / h / 56kg],外周分布体积(V2)和室间清除率(Q)与体重成指数增加(分别为0.62、1.20、0.76),V1与体重成线性关系[4.11 L / 56kg]体重。模拟显示,典型成年人(体重为48.6–99.6千克)中EC50 thr-ult (0.37 mg / L)平均含有0.048 mg / L S-酮咯酸,而EC50 thr-ult 在典型婴儿中的含量为0.032–0.036 mg / L S-酮咯酸(体重5.3–10.6 kg)。为了达到典型婴儿(体重5.3–10.6 kg)中成人S-对映体的浓度(0.048 mg / L),EC 50thr-婴儿分别应为0.49–0.46 mg / L。结论描述了酮咯酸的对映体特异性成熟PK。随后的模拟显示,外消旋阈值EC 50 上S-和R-酮咯酸的比例存在差异。相同的S-酮咯酸浓度需要更高的EC50 thr-婴儿到EC50 thr-成人

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号